Skip to main navigation
Iovance Biotherapeutics
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn
 
 
  • Home
  • Our Company
    • About Iovance Biotherapeutics
    • Management
    • Board of Directors
    • Research Partners & Collaborators
  • Our Science
    • About TIL
    • Our T-cell Therapy Platforms
    • Scientific Publications & Presentations
    • Next Generation Research
  • Our Technology
    • Iovance Cell
      Therapy Center
    • Manufacturing
    • Intellectual Property
  • Our Pipeline
    • Clinical Pipeline
    • Clinical Trials
    • Expanded Access Policy
  • Careers
    • Current Opportunities
    • Our Culture
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn

Press Releases

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Ownership Summary
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
    • Earnings Estimates
  • Fundamentals
    • Snapshot
    • Trading Statistics
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Ratios
  • Corporate Governance
    • Governance Highlights
    • Committee Composition
Investor Toolkit
  • Print Page
  • RSS
  • Email Alerts
  • May 26, 2023 Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
    Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma SAN CARLOS, Calif. , May 26, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.
    View
  • May 09, 2023 Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
    First Biologics License Application (BLA) Submission Completed in March 2023 Commercial Readiness Activities on track to Support Potential Commercial Launch of Lifileucel in 2023 SAN CARLOS, Calif. , May 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.
    View
  • May 02, 2023 Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023
    SAN CARLOS, Calif. , May 02, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter 2023 financial results on Tuesday, May 9, 2023 .
    View
  • Apr 24, 2023 Iovance Biotherapeutics to Present at Upcoming Conferences
    SAN CARLOS, Calif. , April 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences: Chardan's 7 th Annual
    View
  • Mar 24, 2023 Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
    First TIL Therapy BLA Submission to U.S. Food and Drug Administration SAN CARLOS, Calif. , March 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced it has completed its
    View
  • Mar 01, 2023 Iovance Biotherapeutics to Present at Upcoming Conferences
    SAN CARLOS, Calif. , March 01, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences: H.C.
    View
  • Feb 28, 2023 Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
    First Biologics License Application (BLA) Submission on Track to Complete in 1Q23 SAN CARLOS, Calif. , Feb. 28, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating
    View
  • Feb 21, 2023 Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
    SAN CARLOS, Calif. , Feb. 21, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 .
    View
  • Jan 23, 2023 Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
    Acquisition of Worldwide Rights to Proleukin ® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy Positive FDA Feedback on Phase 3 Confirmatory Study in Frontline Advanced (Metastatic or Unresectable) Melanoma Positive Clinical Data in
    View
Iovance Biotherapeutics
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn
© 2023 IOVANCE Biotherapeutics, Inc. All Rights Reserved. IOVANCE logo is a trademark owned
by IOVANCE Biotherapeutics, Inc.
  • Privacy Notice
  • Terms of Use
COOKIE NOTIFICATION

This website uses cookies to improve the site and user experience. By continuing to browse the site, you agree to accept our use of cookies. For more information, please review our cookie policy.

Accept